No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Ahmet Yalcinkaya; Marco Cavalli; Axel Cederholm; Maribel Aranda-Guillén; Anish Behere; Hedvig Mildner; Tadepally Lakshmikanth; Laura Gonzalez; Constantin Habimana Mugabo; Anette Johnsson; Olov Ekwall; Olle Kämpe; Sophie Bensing; Petter Brodin; Pär Hallberg; Mia Wadelius; Nils Landegren

doi:10.1038/s41541-024-00829-9

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

NPJ Vaccines. 2024 Feb 22;9(1):42. doi: 10.1038/s41541-024-00829-9.

Authors

Ahmet Yalcinkaya^{1

2}, Marco Cavalli^{3

4}, Axel Cederholm⁵, Maribel Aranda-Guillén⁶, Anish Behere⁵, Hedvig Mildner⁵, Tadepally Lakshmikanth⁷, Laura Gonzalez⁷, Constantin Habimana Mugabo⁷, Anette Johnsson⁷, Olov Ekwall^{8

9}, Olle Kämpe^{6

10

11}, Sophie Bensing^{11

12}, Petter Brodin^#^{7

13}, Pär Hallberg^#⁴, Mia Wadelius^#⁴, Nils Landegren^#^{14

15}

Affiliations

¹ Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. [email protected].
² Department of Medical Biochemistry, Hacettepe University Hospital, Ankara, Turkey. [email protected].
³ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
⁴ Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
⁵ Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
⁶ Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.
⁷ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
⁸ Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
⁹ Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
¹⁰ Department of Clinical Science, University of Bergen, Bergen, Norway.
¹¹ Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
¹² Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
¹³ Department of Immunology & Inflammation, Imperial College London, London, UK.
¹⁴ Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. [email protected].
¹⁵ Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden. [email protected].

^# Contributed equally.

Abstract

Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

Abstract

Grants and funding